QQQ   385.05 (-0.58%)
AAPL   192.32 (-0.57%)
MSFT   368.80 (-1.00%)
META   317.45 (-0.26%)
GOOGL   130.02 (-0.74%)
AMZN   144.52 (-1.61%)
TSLA   239.37 (+0.27%)
NVDA   455.03 (-2.28%)
NIO   7.76 (+4.44%)
BABA   71.51 (-1.20%)
AMD   116.82 (-1.32%)
T   16.95 (-1.57%)
F   10.70 (+0.94%)
MU   73.13 (-0.76%)
CGC   0.70 (+4.49%)
GE   119.82 (-0.34%)
DIS   91.51 (+0.79%)
AMC   6.79 (-3.28%)
PFE   28.81 (-1.00%)
PYPL   59.53 (+2.78%)
XOM   99.11 (-1.32%)
QQQ   385.05 (-0.58%)
AAPL   192.32 (-0.57%)
MSFT   368.80 (-1.00%)
META   317.45 (-0.26%)
GOOGL   130.02 (-0.74%)
AMZN   144.52 (-1.61%)
TSLA   239.37 (+0.27%)
NVDA   455.03 (-2.28%)
NIO   7.76 (+4.44%)
BABA   71.51 (-1.20%)
AMD   116.82 (-1.32%)
T   16.95 (-1.57%)
F   10.70 (+0.94%)
MU   73.13 (-0.76%)
CGC   0.70 (+4.49%)
GE   119.82 (-0.34%)
DIS   91.51 (+0.79%)
AMC   6.79 (-3.28%)
PFE   28.81 (-1.00%)
PYPL   59.53 (+2.78%)
XOM   99.11 (-1.32%)
QQQ   385.05 (-0.58%)
AAPL   192.32 (-0.57%)
MSFT   368.80 (-1.00%)
META   317.45 (-0.26%)
GOOGL   130.02 (-0.74%)
AMZN   144.52 (-1.61%)
TSLA   239.37 (+0.27%)
NVDA   455.03 (-2.28%)
NIO   7.76 (+4.44%)
BABA   71.51 (-1.20%)
AMD   116.82 (-1.32%)
T   16.95 (-1.57%)
F   10.70 (+0.94%)
MU   73.13 (-0.76%)
CGC   0.70 (+4.49%)
GE   119.82 (-0.34%)
DIS   91.51 (+0.79%)
AMC   6.79 (-3.28%)
PFE   28.81 (-1.00%)
PYPL   59.53 (+2.78%)
XOM   99.11 (-1.32%)
QQQ   385.05 (-0.58%)
AAPL   192.32 (-0.57%)
MSFT   368.80 (-1.00%)
META   317.45 (-0.26%)
GOOGL   130.02 (-0.74%)
AMZN   144.52 (-1.61%)
TSLA   239.37 (+0.27%)
NVDA   455.03 (-2.28%)
NIO   7.76 (+4.44%)
BABA   71.51 (-1.20%)
AMD   116.82 (-1.32%)
T   16.95 (-1.57%)
F   10.70 (+0.94%)
MU   73.13 (-0.76%)
CGC   0.70 (+4.49%)
GE   119.82 (-0.34%)
DIS   91.51 (+0.79%)
AMC   6.79 (-3.28%)
PFE   28.81 (-1.00%)
PYPL   59.53 (+2.78%)
XOM   99.11 (-1.32%)

Design Therapeutics Stock Price, News & Analysis (NASDAQ:DSGN)

$2.45
+0.01 (+0.41%)
(As of 12/6/2023 ET)
Compare
Today's Range
$2.42
$2.51
50-Day Range
$1.99
$2.51
52-Week Range
$1.94
$13.94
Volume
426,261 shs
Average Volume
534,557 shs
Market Capitalization
$137.20 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.67

Design Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
131.3% Upside
$5.67 Price Target
Short Interest
Bearish
9.61% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Acquiring Shares
$49,350 Bought Last Quarter
Proj. Earnings Growth
Decreasing
From ($1.30) to ($1.38) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.93 out of 5 stars

Medical Sector

586th out of 955 stocks

Pharmaceutical Preparations Industry

244th out of 402 stocks


DSGN stock logo

About Design Therapeutics Stock (NASDAQ:DSGN)

Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. The company's portfolio of products comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function, eventually leading to neurological, cardiac, and metabolic dysfunction; and Myotonic Dystrophy Type-1 (DM1), a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs. It is also developing GeneTAC product candidate portfolio for the treatment of other nucleotide repeat expansion-driven monogenic diseases, such as Fragile X syndrome, spinocerebellar ataxias, amyotrophic lateral sclerosis, frontotemporal dementia, Huntington disease, and spinobulbar muscular atrophy. The company was incorporated in 2017 and is headquartered in Carlsbad, California.

DSGN Stock Price History

DSGN Stock News Headlines

All the trading advice you’ve ever received boils down to this
All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.
Design Therapeutics (NASDAQ: DSGN)
All the trading advice you’ve ever received boils down to this
All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.
Why Is Design Therapeutics Stock Moving Lower Today?
DSGN - Design Therapeutics, Inc.
See More Headlines
Receive DSGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Design Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/13/2023
Today
12/06/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
3/12/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:DSGN
Fax
N/A
Employees
57
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$5.67
High Stock Price Target
$6.00
Low Stock Price Target
$4.00
Potential Upside/Downside
+128.5%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
7 Analysts

Profitability

Net Income
$-63,310,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$230,000.00
Book Value
$5.85 per share

Miscellaneous

Free Float
41,609,000
Market Cap
$138.88 million
Optionable
Not Optionable
Beta
1.62
(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

  • Mr. Pratik Shah Ph.D. (Age 53)
    Co-Founder, President, CEO, Principal Financial Officer & Executive Chairperson
    Comp: $638.46k
  • Dr. Sean Jeffries Ph.D. (Age 43)
    Chief Operating Officer
    Comp: $572.21k
  • Dr. Aseem Z. Ansari Ph.D.
    Co-Founder & Scientific Advisor
  • Ms. Julie D. Burgess CPA
    Chief Accounting Officer
  • Dr. Elizabeth Gordon Ph.D.
    Senior Vice President of Regulatory Affairs
  • Dr. Jae B. Kim FACC (Age 53)
    M.D., Chief Medical Officer
  • Ms. Dawn Giangiulio
    Controller














DSGN Stock Analysis - Frequently Asked Questions

Should I buy or sell Design Therapeutics stock right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Design Therapeutics in the last year. There are currently 7 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" DSGN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in DSGN, but not buy additional shares or sell existing shares.
View DSGN analyst ratings
or view top-rated stocks.

What is Design Therapeutics' stock price target for 2024?

7 Wall Street research analysts have issued 1-year price objectives for Design Therapeutics' stock. Their DSGN share price targets range from $4.00 to $6.00. On average, they expect the company's stock price to reach $5.67 in the next twelve months. This suggests a possible upside of 131.3% from the stock's current price.
View analysts price targets for DSGN
or view top-rated stocks among Wall Street analysts.

How have DSGN shares performed in 2023?

Design Therapeutics' stock was trading at $10.26 at the beginning of the year. Since then, DSGN shares have decreased by 76.1% and is now trading at $2.45.
View the best growth stocks for 2023 here
.

When is Design Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 12th 2024.
View our DSGN earnings forecast
.

How were Design Therapeutics' earnings last quarter?

Design Therapeutics, Inc. (NASDAQ:DSGN) released its quarterly earnings data on Monday, November, 13th. The company reported ($0.28) EPS for the quarter, topping analysts' consensus estimates of ($0.42) by $0.14.

What ETFs hold Design Therapeutics' stock?

ETFs with the largest weight of Design Therapeutics (NASDAQ:DSGN) stock in their portfolio include Virtus LifeSci Biotech Clinical Trials ETF (BBC).iShares Neuroscience and Healthcare ETF (IBRN).

When did Design Therapeutics IPO?

(DSGN) raised $228 million in an IPO on Friday, March 26th 2021. The company issued 12,000,000 shares at $18.00-$20.00 per share. Goldman Sachs, SVB Leerink and Piper Sandler served as the underwriters for the IPO.

Who are Design Therapeutics' major shareholders?

Design Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include RTW Investments LP (4.49%), Principal Financial Group Inc. (1.28%), Walleye Capital LLC (0.67%), Assenagon Asset Management S.A. (0.44%), Prescott Group Capital Management L.L.C. (0.32%) and Charles Schwab Investment Management Inc. (0.31%). Insiders that own company stock include Arsani William, Deepa Prasad, Joao Md Siffert, Rodney W Lappe, Simeon George, Sr One Capital Fund I Aggregat and Stella Xu.
View institutional ownership trends
.

How do I buy shares of Design Therapeutics?

Shares of DSGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:DSGN) was last updated on 12/6/2023 by MarketBeat.com Staff

My Account -